Concord Drugs Complete Financial Statements
In FY2025, Concord Drugs (CONCORD) reported revenue ₹10 Cr, net profit ₹0 Cr and EPS ₹0.19. Full financial statements from FY2022 to FY2025 (4 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see CONCORD share price screener.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
CONCORD Revenue, Net Profit & EBITDA — Year-on-Year Growth
CONCORD YoY (Sept 2024 vs Sept 2025) — revenue -16.7%, expenses -25.0%. Review CONCORD earnings valuation to evaluate earnings-based valuation against sector peers.
CONCORD Income Statement — Revenue, EBITDA & Net Profit
Concord Drugs revenue ₹10 Cr, EBITDA ₹1 Cr, net profit ₹0 Cr, EPS ₹0.19 (2025). Explore CONCORD investment value to estimate fundamental worth using multiple valuation models.
| Particulars | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 10 | 14 | 17 | 12 | 16 | 12 | 11 | 8 | 12 | 9 | 13 | 14 | 16 | 13 | 14 |
| Expenses | 9 | 9 | 13 | 16 | 12 | 15 | 11 | 9 | 6 | 11 | 8 | 12 | 13 | 15 | 12 | 12 |
| EBITDA | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Operating Profit Margin % | 11.00% | 10.00% | 7.00% | 5.00% | 7.00% | 2.00% | 7.00% | 13.00% | 21.00% | 8.00% | 16.00% | 5.00% | 9.00% | 4.00% | 8.00% | 11.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Earnings Per Share (₹) | 0.19 | 0.04 | 0.12 | 0.16 | 0.04 | -0.34 | 0.03 | 0.23 | 0.60 | 0.17 | 0.53 | -0.24 | 0.21 | 0.03 | 0.21 | 0.52 |
CONCORD Balance Sheet — Assets, Liabilities & Shareholders' Equity
CONCORD total assets ₹65 Cr, total equity ₹34 Cr, total liabilities ₹ Cr (2025).
| Particulars | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| Total Assets | 65 | 59 | 58 | 56 |
| Current Assets | 41 | 38 | 44 | 42 |
| Fixed Assets | 12 | 12 | 13 | 14 |
| Capital Work in Progress | 2 | 2 | 1 | 1 |
| Investments | 1 | 1 | 1 | 0 |
| Other Assets | 50 | 45 | 44 | 42 |
| LIABILITIES | ||||
| Total Liabilities | ||||
| Current Liabilities | 5 | 4 | 5 | 4 |
| Non-Current Liabilities | ||||
| SHAREHOLDERS' EQUITY | ||||
| Total Equity | 34 | 34 | 32 | 28 |
| Share Capital | 10 | 10 | 9 | 9 |
| Reserves & Surplus | 24 | 24 | 22 | 20 |
CONCORD Cash Flow Statement — Operating, Investing & Financing
Concord Drugs operating cash flow ₹4 Cr, investing ₹-2 Cr, financing ₹-1 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 |
|---|---|---|---|---|
| Operating Activities | 4 | 1 | 2 | 1 |
| Investing Activities | -2 | -1 | -2 | -2 |
| Financing Activities | -1 | 0 | 1 | 2 |
| Net Cash Flow | 0 | 0 | 0 | 0 |